Cronograma de promoção Gilead Sciences
Agenda avançada
Gráfico simples
Sobre a empresa Gilead Sciences
Gilead Sciences, Inc., биофармацевтическая компания, основанная на исследованиях, обнаруживает, разрабатывает и продает лекарства для удовлетворения неудовлетворенных медицинских потребностей в США, Европе и на международном уровне. Компания предоставляет продукты Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera / Eviplera, Stribild и Atripla для лечения инфекции, вызванной вирусом иммунодефицита человека (ВИЧ); Веклуры, инъекция для внутривенного введения, для лечения коронавирусной болезни 2019; и Epclusa, Harvoni, Vosevi, Vemlidy и Viread для лечения заболеваний печени. mais detalhesIPO date | 1992-01-22 |
---|---|
ISIN | US3755581036 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Див.доход ао | 2.7 |
Дивиденд ао | 3.87 |
Сайт | http://www.gilead.com |
Цена ао | 113.99 |
Alteração de preço por dia: | 0% (113.99) |
---|---|
Alteração de preço por semana: | -1.77% (116.04) |
Alteração de preço por mês: | +18.57% (96.14) |
Alteração de preço em 3 meses: | +23.39% (92.38) |
Mudança de preço em seis meses: | +37.65% (82.81) |
Mudança de preço por ano: | +53.6% (74.21) |
Mudança de preço em 3 anos: | +79.23% (63.6) |
Mudança de preço em 5 anos: | +101.22% (56.65) |
Mudança de preço em 10 anos: | +39.37% (81.79) |
Mudança de preço desde o início do ano: | +22.04% (93.4) |
|
Subestimação
|
Eficiência
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Obrigação
|
Impulso de crescimento
|
Dividendo, % | Dividendo | Com base nos resultados do período | Compre antes | Data de encerramento do registro | Pagamento antes |
---|---|---|---|---|---|
3.42% | 3.076 | III кв. 2024 | 11.12.2024 | 13.12.2024 | 30.12.2024 |
1.05% | 0.77 | II кв. 2024 | 11.09.2024 | 13.09.2024 | 30.09.2024 |
1.05% | 0.77 | I кв. 2024 | 12.06.2024 | 14.06.2024 | 01.07.2024 |
1.06% | 0.77 | IV кв. 2023 | 12.03.2024 | 14.03.2024 | 29.03.2024 |
0.92% | 0.75 | III кв. 2023 | 12.12.2023 | 14.12.2023 | 29.12.2023 |
0.98% | 0.75 | II кв. 2023 | 12.09.2023 | 14.09.2023 | 29.09.2023 |
0.89% | 0.75 | IV кв. 2022 | 10.03.2023 | 14.03.2023 | 29.03.2023 |
0.83% | 0.73 | III кв. 2022 | 12.12.2022 | 14.12.2022 | 29.12.2022 |
1.14% | 0.73 | II кв. 2022 | 12.09.2022 | 14.09.2022 | 29.09.2022 |
1.16% | 0.73 | I кв. 2022 | 10.06.2022 | 14.06.2022 | 29.06.2022 |
Data da transação | Data de divulgação | Insider | Tipo | Preço | Volume | Quantidade | Compartilhe até, % | Compartilhe depois, % | Documento |
---|---|---|---|---|---|---|---|---|---|
12.02.2025 | 13.02.2025 | Dickinson Andrew D Chief Financial Officer |
Oferta | 102.22 | 14 073 200 | 137676 | 0 | -0.01 | link |
12.02.2025 | 13.02.2025 | Dickinson Andrew D Chief Financial Officer |
Comprar | 67.27 | 9 261 460 | 137676 | 0 | 0.01 | link |
31.01.2025 | 03.02.2025 | Dickinson Andrew D Chief Financial Officer |
Oferta | 97.22 | 13 822 700 | 142180 | 0 | -0.01 | link |
31.01.2025 | 03.02.2025 | Dickinson Andrew D Chief Financial Officer |
Comprar | 67.52 | 9 599 990 | 142180 | 0 | 0.01 | link |
31.01.2025 | 31.01.2025 | MERDAD V PARSEY Officer |
Comprar | 98 | 18 098 900 | 184683 | 0 | 0.01 | link |
15.01.2025 | 16.01.2025 | Dickinson Andrew D Chief Financial Officer |
Oferta | 91.35 | 228 375 | 2500 | 0 | 0 | link |
19.12.2024 | 23.12.2024 | GILEAD SCIENCES, INC. 10% Owner |
Comprar | 21.37 | 20 098 500 | 940499 | 0 | 0.08 | link |
29.11.2024 | 03.12.2024 | Dickinson Andrew D Chief Financial Officer |
Oferta | 92.76 | 23 064 300 | 248645 | 0 | -0.02 | link |
29.11.2024 | 03.12.2024 | Dickinson Andrew D Chief Financial Officer |
Comprar | 70.5 | 17 529 500 | 248645 | 0 | 0.02 | link |
29.11.2024 | 29.11.2024 | ANDREW DICKINSON Officer |
Comprar | 92.76 | 23 064 300 | 248645 | 0 | 0.02 | link |
27.11.2024 | 29.11.2024 | Parsey Merdad Chief Medical Officer |
Oferta | 91.92 | 15 094 300 | 164211 | 0 | -0.01 | link |
27.11.2024 | 29.11.2024 | Parsey Merdad Chief Medical Officer |
Comprar | 62.44 | 9 079 590 | 145413 | 0 | 0.01 | link |
12.09.2024 | 13.09.2024 | Parsey Merdad Chief Medical Officer |
Oferta | 84.5 | 1 795 290 | 21246 | 0 | 0 | link |
12.09.2024 | 13.09.2024 | Parsey Merdad Chief Medical Officer |
Comprar | 57.92 | 1 448 000 | 25000 | 0 | 0 | link |
12.09.2024 | 13.09.2024 | Mercier Johanna Chief Commercial Officer |
Oferta | 83.78 | 2 459 530 | 29357 | 0 | 0 | link |
01.07.2024 | 01.07.2024 | Parsey Merdad Chief Medical Officer |
Oferta | 68.63 | 137 260 | 2000 | 0 | 0 | link |
29.02.2024 | 29.02.2024 | Parsey Merdad Chief Medical Officer |
Oferta | 72.74 | 598 650 | 8230 | 0 | 0 | link |
28.02.2024 | 29.02.2024 | Parsey Merdad Chief Medical Officer |
Oferta | 73.18 | 146 360 | 2000 | 0 | 0 | link |
16.01.2024 | 17.01.2024 | Dickinson Andrew D Chief Financial Officer |
Oferta | 85.78 | 428 900 | 5000 | 0 | 0 | link |
09.01.2024 | 10.01.2024 | Mercier Johanna Chief Commercial Officer |
Oferta | 85.23 | 702 466 | 8242 | 0 | 0 | link |
20.07.2023 | 21.07.2023 | Dickinson Andrew D Chief Financial Officer |
Oferta | 80 | 400 000 | 5000 | 0 | 0 | link |
01.02.2022 | 02.02.2022 | Pletcher Brett A EVP,Corp Affairs & Gen Counsel |
Oferta | 68.54 | 963 741 | 14061 | 0 | 0 | link |
Instituições | Volume | Compartilhar, % |
---|---|---|
Blackrock Inc. | 122793011 | 9.86 |
Vanguard Group Inc | 111822428 | 8.98 |
Capital World Investors | 83364123 | 6.7 |
Capital Research Global Investors | 59657126 | 4.79 |
State Street Corporation | 59536425 | 4.78 |
Dodge & Cox Inc | 33295023 | 2.67 |
Geode Capital Management, LLC | 25274185 | 2.03 |
Wellington Management Group, LLP | 18630134 | 1.5 |
Morgan Stanley | 17801718 | 1.43 |
FMR, LLC | 17097648 | 1.37 |
Supervisor | Cargo | Pagamento | Ano de nascimento |
---|---|---|---|
Mr. Andrew D. Dickinson | Chief Financial Officer | 2.66M | 1970 (55 anos) |
Ms. Johanna Mercier | Chief Commercial Officer | 3.1M | 1970 (55 anos) |
Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer | 2.79M | 1963 (62 ano) |
Ms. Jacquie Ross C.F.A. | Vice President of Investor Relations | N/A | |
Ms. Jyoti K. Mehra | Executive Vice President of Human Resources | N/A | 1977 (48 anos) |
Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation & Portfolio | N/A | 1962 (63 ano) |
Ms. Sandra Patterson | Senior VP, Corporate Controller & Principal Accounting Officer | N/A | 1967 (58 anos) |
Dr. Rudolf Ertl | Senior Vice President of Commercial Operations of Australia, Canada, Europe | N/A | 1946 (79 anos) |
Mr. Daniel P. O'Day | Chairman & CEO | 1964 (61 ano) | |
Ms. Deborah H. Telman | Executive VP of Corporate Affairs, General Counsel & Corporate Secretary | 1965 (60 anos) |
Endereço: United States, Foster City, CA , 333 Lakeside Drive - abrir no Google Maps, abrir mapas Yandex
Site: http://www.gilead.com
Site: http://www.gilead.com